手机版现金连环夺宝

当前位置:  首页 > Introduction

Introduction

About us

Sichuan Industrial Institute of Antibiotics (SIIA) founded in 1965 is one of the major pharmaceutical research and development (R&D) institutes in China which was directly under the SFDA. In 2013 SIIA was affiliated to Chengdu University. Now SIIA focuses on the R&D of new medicines and industrial process for manufacturing drugs.

 

In SIIA, there are 132 researchers including 47 full and associate professors, 58 PhDs, 4 provincial academic and technological foregoer candidates, 4 experts enjoying special government allowance, 31 Master supervisors, and 62 Master candidates. It has 6 master-degree specialties (medical chemistry, microbial and biochemical pharmacy, pharmaceutics, pharmaceutical analysis, pharmacology, biochemical engineering). The research orientation includes microbial medicine, synthetic drugs, biotech drugs, natural plant medicines and pharmaceutical preparations, etc.. SIIA has 3 centers: National Center of Antibiotic Culture Collection, Efficacy Evaluation Center of Antibiotics, and Drug Analysis and Detection Center. With these centers, many divisions have been set up including Antibiotic Research and Re-evaluation Key Laboratory of Sichuan Province, Laboratories for pharmaceutical analysis, evaluation, quality control, etc.; Libraries such as microbial strains library, drug synthetic genes library, natural products library, anti-infective drugs library, and pharmaceutical compounds library, etc..

 

With the long history and abundant experience in antibiotic medicines R&D, SIIA has launched the partnership with over 200 corporations, 20 of which are among the top 100 pharmaceutical corporations in China. With the purpose of expanding the cooperation scope and fostering the discovery and development of novel drugs, 6 alliances between the institutes and corporations have been established. Over 90% of antibiotic medicines are developed from SIIA.

 

SIIA’s parterns are not only inside China but also outside of China. Since 1986, SIIA initiated the international cooperation with governments, institutes, universities, corporations, and individuals from United Nation Development Programm (UNDP), Russia, America, Japan, Britain, etc. in many ways. In 2009, SIIA was duly authorized as the International Science and Technology Cooperation Base supported by the Ministry of Science and Technology. Cooperated with Russia, the research on beta-lactam has been adopted by the Sino-Russia government S&T cooperation program; the research on cephalosprins was funded by major projects of International Cooperation Ministry of Science and Technology from 2007 to 2010; with Japan, a medicine microoganism bank with 50,000 strains has been established. SIIA is in the frontier of antibiotic medicine discovery and development and reaches the international level in this research field. It is now dedicated in the expanding international cooperations in different fields with different countries.

 

The past half century has witnessed the development and achievements of SIIA. With years efforts, SIIA developed the new anti-TB drug Rifapentine and a new therapy for TB which were spoken highly of by WHO and won the National Award for Invention 2nd Prize. The discovery and development of rifamycins has made a great contribution to prevention and treatment of TB.

 

Through several generations’ efforts, SIIA has become one of the leading interdisciplinary centers of excellence in China. The institute gives great emphasis on creativity and practicability of key theory and core technology in pharmaceutical research, and more and more drugs will be applied for clinic trail. Bearing the spirit of “pursuit the excellence” and “huamanism”,SIIA’s people will do their best to make more contributions to human and their health.   

手机版现金连环夺宝(以下简称手机版现金连环夺宝)1965年因国家战备需要内迁至成都建所,2013年整体划转并入成都学院(成都大学)。
        手机版现金连环夺宝专注抗生素领域的研发及成果转化48年,建设学术型药学硕士学位点32年,形成了专注于药物品种研发及产业化的完整科研体系,科研成果产业化率始终保持在95%以上,实现了近百个药物品种的产业化。拥有“科技部国际科技合作基地”、“国家新抗生素菌种保藏中心”、“国家新抗生素工业性实验基地”、“抗生素研究与再评价四川省重点实验室”等国家、省级科研平台,在药物工艺研发和产业化领域具有极高的行业知名度,综合研发及成果转化实力处于国内领先地位。

?